AI assistant
Ernexa Therapeutics Inc. — Director's Dealing 2021
Apr 20, 2021
35259_dirs_2021-04-20_80340323-334e-4e14-b392-04f7d08995d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-04-16
Reporting Person: Federoff Howard J. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-16 | Stock Option | $7.94 | A | 2627915 | Acquired | 2031-04-15 | Common Stock (2627915) | Direct |
| 2021-04-16 | Stock Option | $7.94 | A | 597253 | Acquired | 2031-04-15 | Common Stock (597253) | Direct |
Footnotes
F1: The option vests and becomes exercisable over four years, with 656,979 shares vesting on April 16, 2022, 54,748 shares vesting on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 shares vesting on April 16, 2025, subject to continued service through each vesting date.
F2: The option vests and becomes exercisable in full upon the occurrence of the first approval by the Food and Drug Administration of an investigational new drug application in connection with that certain license among the Issuer, Factor Biosciences Therapeutics Limited and Novellus Therapeutics Limited, subject to continued service through such vesting date.